7 results about "Oral Powder" patented technology

A powder mixture for oral delivery of active ingredients includes a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles. At least one of the at least two types of sugar alcohol particles takes the form of i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles. At least one of the at least two types of sugar alcohol particles has a particle size with more than 50% of the particles being below 250 microns, and at least one of the at least two types of sugar alcohol particles is present in an amount of at least 20% by weight of the powder mixture.

The present invention relates to a solid oral powder filled hard gelatin capsule formulation of tafamidis, a pharmaceutically acceptable salt thereof, or tafamidis co-crystal(s), which involves use of standard dry blending ingredients and provides an improved dissolution profile. The formulation includes an effective amount of tafamidis, a pharmaceutically acceptable salt thereof, or a tafamidis co-crystal(s), at least one solubilizing agent; and at least one excipient selected from diluent, disintegrant and lubricant.

The present invention relates to a solid oral powder filled hard gelatin capsule formulation of tafamidis, a pharmaceutically acceptable salt thereof, or tafamidis co-crystal(s), which involves use of standard dry blending ingredients and provides an improved dissolution profile. The formulation includes an effective amount of tafamidis, a pharmaceutically acceptable salt thereof, or a tafamidis co-crystal(s), at least one solubilizing agent; and at least one excipient selected from diluent, disintegrant and lubricant.

The invention relates to the technical field of animal stress regulation and control, in particular to a preparation method and application of a cattle specific stress blocker, and the preparation method comprises the following steps: Fmoc solid-phase synthesis of specific sequence cattle CRH receptor antagonist peptide, pretreatment of theanine, GABA and taurine; under the protection of nitrogen at 25 DEG C, compounding the active component with a maltodextrin-beta-cyclodextrin carrier in a ratio of 5: 1, and adding potassium sorbate; the CRH receptor binding constant Kd of the blocking agent reaches 1.2 * 10 <-9 > mol / L, the blocking agent can be fed in a mixed mode 30 minutes before transportation, fed in a mixed mode 1 hour before group transfer or fed in a drenching mode 1 hour after temperature shock stress according to the dosage of 10 g / head, the stress reaction of cattle is efficiently blocked, and the breeding benefits are guaranteed.

The invention relates to a powder mixture for the oral administration of active ingredients. The powder mixture comprises a particle population and one or more active ingredients. The particle population includes at least two types of sugar alcohol particles, wherein: at least one of said at least two types of sugar alcohol particles comprises i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles; at least one of said at least two types of sugar alcohol particles has a particle size with more than 50% of the particles below 250 microns; and at least one of said at least two types of sugar alcohol particles is present in an amount of at least 20% by weight of the powder mixture.

The invention discloses sustained-release oral powder for treating osteoporosis and a preparation method of the sustained-release oral powder. The sustained-release oral powder comprises 2 parts of a supramolecular metal organic framework material sMOF, 0.8-1.0 part of microcrystalline cellulose and 0.1-0.2 part of magnesium stearate. Wherein the supramolecular metal organic framework material sMOF is formed by coordination self-assembly of Sr < 2 + >, Mg < 2 + >, alendronate (ALN), 1, 6-fructose diphosphate sodium salt (FDP) and casein phosphopeptides (CPP). The powder has excellent treatment effect, biocompatibility and slow release characteristic, can effectively promote osteoblast differentiation, inhibit osteoclast activity and reverse bone mineral density decline, and is suitable for treatment of bone diseases such as osteoporosis and fracture.

A method for preventing and treating porcine infectious diarrhea, wherein lysophosphatidic acid is used as a feed additive for preventing and treating porcine infectious diarrhea, and the porcine infectious diarrhea is caused by Escherichia coli. The feed additive is a premix prepared by means of mixing lysophosphatidic acid and a carrier, and the dosage form thereof is an oral powder or granule, and the dosage of the lysophosphatidic acid premix added to the feed is 0.1%-0.5% of the total weight of the feed.